title: Re: Rituximab monotherapy is highly effective in splenic marginal zone lymphoma.
authors.forename: Michael
authors.initials: M
authors.lastname: Bennett
authors.forename: Shaiy
authors.initials: S
authors.lastname: Yegena
authors.forename: Harish P
authors.initials: HP
authors.lastname: Dave
authors.forename: Geraldine P
authors.initials: GP
authors.lastname: Schechter
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018572:Disease-Free Survival; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D008875:Middle Aged; D012074:Remission Induction; D012189:Retrospective Studies; D000069283:Rituximab; D013160:Splenic Neoplasms / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab